Cargando…

Thermodynamic and Structural Behavior of α‐Galactosylceramide and C6‐Functionalized α‐GalCer in 2D Layers at the Air–Liquid Interface

α‐Galactosylceramide (α‐GalCer; KRN7000) is a ligand for the glycoprotein CD1d that presents lipid antigens to natural killer T cells. Therefore, KRN7000 as well as some modified versions thereof have been widely investigated as part of novel immunotherapies. To examine the impact of structural modi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brezesinski, Gerald, Calow, Adam D. J., Pereira, Claney L., Seeberger, Peter H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Full Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004034/ https://www.ncbi.nlm.nih.gov/pubmed/31544285 http://dx.doi.org/10.1002/cbic.201900491

Ejemplares similares

A Multifactorial Mechanism in the Superior Antimalarial Activity of α-C-GalCer
por: Schmieg, John, et al.
Publicado: (2010)

Synthesis of a 2''-Deoxy-β-GalCer
por: Thakur, Meena S., et al.
Publicado: (2014)

Interaction between Bacteria and the Immune System for Cancer Immunotherapy: The α-GalCer Alliance
por: Ustjanzew, Arsenij, et al.
Publicado: (2022)

α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials
por: Zhang, Yingting, et al.
Publicado: (2019)

Galactosylsphingamides: new α-GalCer analogues to probe the F’-pocket of CD1d
por: Guillaume, Joren, et al.
Publicado: (2017)

6″-Modifed α-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria
por: Meijlink, Michael A., et al.
Publicado: (2022)

Modulation of NKT cells and Th1/Th2 imbalance after α-GalCer treatment in progressive load-trained rats
por: Ru, Wang, et al.
Publicado: (2009)

Encapsulation of MERS antigen into α-GalCer-bearing-liposomes elicits stronger effector and memory immune responses in immunocompetent and leukopenic mice
por: Khan, Masood Alam, et al.
Publicado: (2022)

Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors
por: Li, Yan-Ruide, et al.
Publicado: (2022)

A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine
por: Feng, Huapeng, et al.
Publicado: (2022)

Immunomodulatory Cell Therapy Using αGalCer-Pulsed Dendritic Cells Ameliorates Heart Failure in a Murine Dilated Cardiomyopathy Model
por: Ikeda, Masataka, et al.
Publicado: (2022)

Immune Modulating Effects of NKT Cells in a Physiologically Low Dose Leishmania major Infection Model after αGalCer Analog PBS57 Stimulation
por: Griewank, Klaus G., et al.
Publicado: (2014)

Crystal Structures of Bovine CD1d Reveal Altered αGalCer Presentation and a Restricted A’ Pocket Unable to Bind Long-Chain Glycolipids
por: Wang, Jing, et al.
Publicado: (2012)

Repeated α-GalCer Administration Induces a Type 2 Cytokine-Biased iNKT Cell Response and Exacerbates Atopic Skin Inflammation in Vα14(Tg) NC/Nga Mice
por: Park, Hyun Jung, et al.
Publicado: (2021)

A Designed α‐GalCer Analog Promotes Considerable Th1 Cytokine Response by Activating the CD1d‐iNKT Axis and CD11b‐Positive Monocytes/Macrophages
por: Ma, Juan, et al.
Publicado: (2020)

A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II–IIIA non-small cell lung cancer: study protocol for a randomized controlled trial
por: Saka, Hideo, et al.
Publicado: (2017)

Intra-Peritoneal Hyperthermia Combining α-Galactosylceramide in the Treatment of Ovarian Cancer
por: Wu, Chao-Chih, et al.
Publicado: (2013)

Production of α-Galactosylceramide by a Prominent Member of the Human Gut Microbiota
por: Wieland Brown, Laura C., et al.
Publicado: (2013)

Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs
por: Artiaga, Bianca L., et al.
Publicado: (2022)

Efficient synthesis of α-galactosylceramide and its C-6 modified analogs
por: Li, Huiting, et al.
Publicado: (2022)

Characterization of a Glycolipid Synthase Producing α-Galactosylceramide in Bacteroides fragilis
por: Caballé, Marc, et al.
Publicado: (2022)

The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma
por: Porubsky, Stefan, et al.
Publicado: (2021)

Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies
por: Galili, Uri
Publicado: (2021)

Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells
por: Akutsu, Yasunori, et al.
Publicado: (2002)

Efficient Divergent Synthesis of New Immunostimulant 4″-Modified α-Galactosylceramide Analogues
por: Janssens, Jonas, et al.
Publicado: (2017)

Synthesis and Immunological Activity of Novel Oligo(ethylene glycol) Analogues of α-Galactosylceramide
por: Pawar, Mithun S., et al.
Publicado: (2022)

Conversion of Tumors into Autologous Vaccines by Intratumoral Injection of α-Gal Glycolipids that Induce Anti-Gal/α-Gal Epitope Interaction
por: Galili, Uri
Publicado: (2011)

Course of IgE to α‐Gal in a Swedish population of α‐Gal syndrome patients
por: Apostolovic, Danijela, et al.
Publicado: (2021)

Thermodynamics at Solid–Liquid Interfaces
por: Frank, Michael, et al.
Publicado: (2018)

Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine
por: Gableh, Fateme, et al.
Publicado: (2016)

IgE, α-Gal and atherosclerosis
por: Wilson, Jeffrey M., et al.
Publicado: (2019)

The α-Gal Syndrome and Potential Mechanisms
por: Román-Carrasco, Patricia, et al.
Publicado: (2021)

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma
por: Kikuchi, A, et al.
Publicado: (2001)

The Molecular Basis for Recognition of CD1d/α-Galactosylceramide by a Human Non-Vα24 T Cell Receptor
por: López-Sagaseta, Jacinto, et al.
Publicado: (2012)

Tumor-infiltrating effector cells of α-galactosylceramide-induced antitumor immunity in metastatic liver tumor
por: Osada, Takuya, et al.
Publicado: (2004)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant
por: Artiaga, Bianca L., et al.
Publicado: (2016)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review)
por: HUAI, GUOLI, et al.
Publicado: (2016)

Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases
por: Olivera-Ardid, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lpv8lv0l2d8e2lc6bnq6f90376